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ABSTRACT Using the peptide hormone glucagon and Ab(1–40) as model systems, we have sought to elucidate the mecha-
nisms by which ﬁbrils grow and multiply. We here present real-time observations of growing ﬁbrils at a single-ﬁbril level. Growing
from preformed seeds, glucagon ﬁbrils were able to generate new ﬁbril ends by continuously branching into new ﬁbrils. To our
knowledge, this is the ﬁrst time amyloid ﬁbril branching has been observed in real-time. Glucagon ﬁbrils formed by branching
always grew in the forward direction of the parent ﬁbril with a preferred angle of 35–40. Furthermore, branching never occurred
at the tip of the parent ﬁbril. In contrast, in a previous study by some of us, Ab(1–40) ﬁbrils grew exclusively by elongation of
preformed seeds. Fibrillation kinetics in bulk solution were characterized by light scattering. A growth process with branching,
or other processes that generate new ends from existing ﬁbrils, should theoretically give rise to different ﬁbrillation kinetics
than growth without such a process. We show that the effect of adding seeds should be particularly different in the two cases.
Our light-scattering data on glucagon and Ab(1–40) conﬁrm this theoretical prediction, demonstrating the central role of ﬁbril-
dependent nucleation in amyloid ﬁbril growthINTRODUCTION
The formation of amyloid fibrils involves at least two steps:
the formation of growth centers by primary nucleation,
which is often a slow process, followed by elongation
through addition of monomers. Model systems relying solely
on primary nucleation, as exemplified by polyglutamine
involved in Huntington’s disease (1), could be the exception
rather than the rule. Indeed, very often a third process, a so-
called secondary nucleation mechanism, is inferred, in which
new growth centers are formed from existing fibrils (2–6).
The positive feedback from secondary nucleation theoreti-
cally gives rise to exponential growth kinetics, in agreement
with the reaction profile observed for many proteins.
Although several studies indicate the existence of secondary
nucleation, and its existence has consequences for the
competitive formation of different types of fibrils, the nature
of the mechanisms involved remains unclear (4,6–12).
Fibrillation of the 29-residue peptide hormone glucagon
and the 40-residue amyloid b-peptide, Ab(1–40), has been
comprehensively studied in our groups over the past years.
Glucagon is a hormone involved in regulating blood sugar
levels, and it is used as a drug to treat severe hypoglycemic
incidents in diabetics (13). Glucagon fibrillation kinetics
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0006-3495/09/02/1529/8 $2.00have the characteristics of an exponential reaction: a long
lag phase followed by a sudden increase in fibril mass
(14–17). The fibrillation kinetics of Ab(1–40) have also
been characterized extensively (18–25) because of interest
in the correlation between amyloid plaque formation and
Alzheimer’s disease (26).
In this work, we have used TIRFM to image the growth of
single glucagon fibrils in real time. Adding small amounts of
preformed seeds effectively bypasses primary nucleation and
allows us to focus on the way fibrils grow and multiply. By
TIRFM, glucagon fibrils were observed to continuously form
new fibrils from existing fibrils by branching, whereas pre-
vious work showed fibril growth of Ab(1–40) to be strictly
linear (18,21). Light-scattering experiments on seeded
solutions of glucagon and Ab(1–40) confirm that the fibrilla-
tion kinetics with and without secondary nucleation are
fundamentally different, as predicted by theory.
METHODS
Peptide and seed solutions
In all glucagon experiments, pharmaceutical grade glucagon (Novo Nordisk
A/S, Bagsværd, Denmark) was dissolved to a final concentration of 0.25 mg/
mL (72 mM) in 50mM glycine HCI buffer pH 2.5 sterile filtered through
a 0.22 mm filter. In Ab(1–40) experiments, TFA-salt Ab(1–40) (Biopeptide
Co., Inc., San Diego, CA) was treated as described in reference (27) to
substitute TFA with NaOH and eliminate aggregates. First, the peptide
was dissolved in 0.02 M NaOH until a pH of 11.0 was reached. The solution
was sonicated for 1 min and then lyophilized. Immediately before use, the
lyophilized powder was resuspended in 50 mM phosphate buffer, pH 7.5,
and filtered through a 20-nm filter (Anotop 10, Whatman, Maidstone,
UK). The final Ab(1–40) concentration was 0.22 mg/mL (50 mM). For
doi: 10.1016/j.bpj.2008.11.024
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minute amounts of aggregates were present in the final solution. Peptide
concentrations were determined by absorbance measurements using molar
extinction coefficients of 3
glu
280 ¼ 8250 M1cm1 and 3Ab280 ¼ 1280 M1cm1.
All glucagon experiments were done at 21C, and all Ab(1–40) experiments
were done at 37C. Seed stocks were prepared from already fibrillated
samples prepared under identical conditions. Fibrils were disrupted into
seeds by sonication of the fibril solution with 15 pulses from a tip sonicator,
putting the sample on ice for 1 min to avoid melting of the fibrils, and then
sonicating the sample once again. The seed stock was kept at 5C and briefly
vortex mixed before use. For each peptide, two seed concentrations sepa-
rated by a factor of 10 were used, with one of the seed concentrations chosen
to be identical to the seed concentration in the TIRFM experiments. We note
that the actual concentration of seeds in a seed stock is a relative measure and
that two separate seed stocks were used for the light-scattering and TIRFM
experiments, respectively. The seed concentration is reported as the mass in
micrograms of fibrillated peptide added to 1 mL freshly prepared peptide
solution. The amount of unfibrillated peptide in the seed stock, measured
in the supernatant after spinning a fibril solution for 15 min at 32,000 
g, amounted to <5% of the total peptide concentration, and hence the fibril
kinetics essentially go to completion.
TIRFM
A detailed description of the TIRFM setup and quartz cleaning procedures
are found in earlier work (28). In the case of glucagon, the freshly dissolved
glucagon powder was centrifuged for 15 min at 32,000  g to eliminate
aggregates and undissolved powder. Glucagon seeds in a concentration of
0.1 mg/mL were added to the solution along with 10–30 mM thioflavin T
(ThT). A drop of glucagon solution was placed between a quartz slide glass
and a coverglass, which were then glued together to minimize evaporation.
Within ~1 h, a spot suitable for studying glucagon fibril growth in real time
was selected, and the measurement started. Glucagon fibril growth was
monitored for up to 19 h with a frame every 15–30 min and an accumulation
time of 5–16 s. The frame rate and accumulation time were limited by the
bleaching of ThT molecules. After a complete kinetics measurement, the
appearance of the spherulites outside the laser illumination area was checked
and found to be similar to the spherulites studied. Measurements were
repeated several times on newly prepared samples. By visual inspection,
the sample-to-sample kinetics was identical. Experimental details of the
Ab(1–40) experiments are found in reference (18).
Light scattering
Peptide solutions were filtered through a 20-nm filter (Anotop 10, Whatman)
to eliminate dust and aggregates. Seeds were added immediately before
starting the measurements. Glucagon was mixed with either 0.1 or
1 mg/mL seeds, and Ab(1–40) was mixed with either 0.5 or 5 mg/mL seeds.
In this way, the experimental conditions of the TIRFM experiments were re-Biophysical Journal 96(4) 1529–1536produced while at the same time allowing for a study of how the kinetics re-
sponded to differences in the seed concentration. A single sample solution
was prepared for both SALS and LALS experiments, and the experiments
were started simultaneously by aliquots from the same sample preparation.
Light-scattering experiments were performed on a LALS setup (BI-200SM,
Brookhaven Instruments, Holtsville, NY) and on a SALS setup described
previously (29,8). With the large-angle equipment, the dynamic and static
light scattering was followed at scattering vector q ¼ 23 mm1 (90) by
continuously acquiring data for 5 min. The SALS setup measures the static
signal at scattering vectors 0.02–2 mm1 (0.1–11) every 3–5 min. The scat-
tering volumes for the SALS and LALS setup are 2$103 and 35 mm3,
respectively, and both setups are temperature controlled.
TEM
Glucagon samples were analyzed by TEM as described previously (14).
RESULTS
Fibrillation kinetics was studied by TIRFM and light scat-
tering. TIRFM measures single-fibril growth in real time in
a thin layer close to the surface, whereas light scattering
measures fibril growth in bulk solution. In all experiments,
fibrillation kinetics was initiated by adding small amounts
of preformed seeds. In addition to the kinetics experiments,
glucagon fibril structure was examined by TEM.
TIRFM
Glucagon fibril growth was monitored in real time for up to
19 h with measurements every 15–30 min. In the experi-
ments, 0.25 mg/mL glucagon was seeded with 0.1 mg/mL
preformed seeds. Fig. 1 shows three pictures from a typical
TIRFM measurement captured 0, 5, and 17 h after the exper-
iment was started. The entire measurement is posted online
as Movie S1 in the Supporting Material. The first picture
shows how fibril growth starts from a cluster of seeds and
grows radially in all directions. After 5 h, fibrils have grown
up to 25 mm in length, and spontaneous fibril branching is
observed. At the end of the experiment, fibril growth has
stopped, and a large structure with a diameter of 40–50 mm
has formed. Multiple branching points on the same fibril as
well as new branches on fibrils, themselves formed by
branching, give rise to a relatively dense structure. Fig. 2FIGURE 1 TIRFM pictures showing branched glucagon fibril growth at times specified on the figure. After 5 h, fibrils have grown up to 25 mm in length, and
new fibrils have formed by branching. After 17 h, a relatively dense spherulitic structure has formed. The entire measurement is posted online as a movie
(Movie S1). The bar represents 10 mm.
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experiments. In Fig. 2 a, two fibrils grow in opposite direc-
tions from a small cluster of seeds. Although this could be
interpreted as bidirectional growth, it should be noted that
the optical resolution does not allow for a distinction
between single seeds and clusters of seeds. After 3.5 h,
a new fibril is formed by branching, and this process repeats
itself in the following 2 h, resulting in several new fibrils. In
one case, a fibril grows along the parent fibril for a few
micrometers before leaving at an angle. In Fig. 2 b, a fibril
is observed to grow along the surface. At one point it forms
a kink, and in the following observations, several new fibrils
appear from the side of the fibril. In both panels of Fig. 2
bleaching of ThT is observed to some extent. The entire
measurement in Fig. 2 b is posted online as Movie S2 in
the Supporting Material.
An analysis of 65 branching angles measured with respect
to the direction of growth from the entire surface in Fig. 1
was carried out. In Fig. 3 a, angles have been binned and
plotted in a histogram. All branching angles were in the
range from 15 to 65 relative to the direction of growth of
the parent fibril with a maximum around 35–40. However,
in a number of cases, the newly formed fibrils grew in the
forward direction along the parent fibril for several microm-
eters before protruding at an angle. These zero-angle events
are not included in the histogram. Six individual fibrils,
which all grew from the seeds added initially, were selected
for analysis of growth rates (Fig. S1 in the Supporting Mate-
rial). In Fig. 3 b, the length of each fibril is plotted as a func-
FIGURE 2 Branching detail from two separate TIRFM experiments. In
panel a, two fibrils grow from a cluster of seeds (as indicated by arrow)
in the center of the picture. After 3.3 h, a single branching event along the
fibril is observed. In the following hours, several branches (some indicated
by arrowheads) are observed. In panel b, a fibril grows from a seed in the left
side of the picture. After 1 h, the fibril forms a kink, and in the following
hours a new fibril protrudes close to the kink (arrowhead at t ¼ 2.5 h).
Finally, a cascade of new fibrils is formed (marked by arrowheads), and
at t ¼ 7.3 h, fibrils branching from fibrils formed by branching themselves
are observed. The bar represents 10 mm. The entire measurement is posted
online as a QuickTime movie (Movie S2).tion of time. The final fibril length ranged from 10 to 28 mm.
Occasionally, fibrils exhibited stop-and-run behavior in
which a fibril after a period of continuous growth temporarily
stops growing and then resumes growth. Also, two of the six
fibrils stopped growing after <4 h, although fibrils in their
vicinity kept growing for several hours (fibrils 1 and 6).
Growth rates were calculated for each of the six fibrils
plotted in Fig. 3 b. Initially, growth rates ranged from 40
to 140 nm/min, but after a few hours of growth, the growth
rates decreased to 20–40 nm/min.
TEM
The molecular basis of branching glucagon fibrils was exam-
ined by TEM of samples formed under conditions identical
to the TIRFM experiments. Because TEM sample prepara-
tion involves transfer to a carbon-coated grid and staining
and drying of the sample, care should be taken when inter-
preting TEM pictures. For example, the large, branched
structures observed by TIRFM are likely to be disrupted
during TEM sample preparation. Also, because TIRFM
observations show branching points to be micrometers apart,
they are expected to be rare events in TEM pictures. The
glucagon fibrils had a morphology dominated by two or
several protofilaments twisting periodically around each
other. Fig. 4 a shows a fibril splitting into four individual
fibrils at a single branching point. Fig. 4, b and c, shows
single fibrils splitting into two fibrils with an angle between
the two, and Fig. 4 d shows an example of a fibril splitting
into two individual fibrils, which remain close together after
the branching point.
SALS and LALS
The SALS setup is designed specifically for studying the
growth of large micrometer structures, in this case fibrils,
a b
FIGURE 3 Distribution of branching angles and fibril length versus time
of six individual fibrils from a single real-time experiment. (a) Sixty-five
branching events were measured with respect to the direction of growth of
the parent fibril. Branches most frequently form an angle of 35–40, and
branching opposite the direction of growth was never observed. (b) Length
(mm) of six individual fibrils from a single real-time measurement. Fibrils
exhibited stop-and-run behavior characterized by intervals where no growth
occurs followed by continued growth. The six fibrils measured are shown in
Fig. S1.Biophysical Journal 96(4) 1529–1536
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smaller species. We performed SALS and LALS experi-
ments simultaneously with aliquots from the same sample
preparation. The SALS setup has a scattering volume of
35 mm3 compared to the scattering volume of the LALS
setup of 2$103 mm3. Because of the smaller scattering
volume of the LALS setup, large single particles diffusing
through the scattering volume will completely dominate
the total scattered signal and give rise to sharp spikes in
the signal.
Fig. 5 a shows the fibrillation kinetics of Ab(1–40) seeded
with 0.5 and 5 mg/mL seeds monitored by SALS. At a seed
concentration of 0.5 mg/mL, a linear increase in intensity is
observed for 12 h. With 5 mg/mL of seeds, a 1-h linear
increase in intensity is followed by a plateau as fibrillation
kinetics stop. After 7 h, aggregates start to precipitate, and
as a result, the SALS signal decreases abruptly. The LALS
signal is plotted in Fig. 5 b. In agreement with the small-
angle scattering, a steady linear increase is observed for
more than 12 h at low seed concentration. At high seed
concentration, a linear phase is observed for 90 min followed
by a plateau. By visual inspection, the fibrillated Ab(1–40)
sample at 0.5 mg/mL seed concentration was noticeably
more homogeneous than the sample at 5 mg/mL seed concen-
tration. For both samples, precipitation of fibril aggregates
was visible after the experiment.
Fig. 5 c shows the SALS intensity from 0.25 mg/mL
glucagon solutions seeded with 0.1 and 1 mg/mL seeds as
a function of time. At a seed concentration of 0.1 mg/mL,
the beginning of the reaction profile is dominated by
a long lag phase. After ~10 h, the scattered intensity
increases abruptly and reaches a plateau at the end of the
experiment. Increasing the seed concentration to 1 mg/mL
conserves the general sigmoid reaction profile but increases
the initial scattered intensity, suggesting that the signal at
early times is mainly from the seeds. The lag phase is
reduced to ~5 h. The LALS intensity from seeded solutions
of glucagon is plotted in Fig. 5 d. After some hours with
a relatively moderate increase in scattered intensity, the scat-
FIGURE 4 TEM pictures of branching fibrils. The fibrils do not merely
twine or untwine because the total number of filaments that make up the
fibrils seems to be larger after branching. (a) In some cases, a single fibril
was observed to split into several fibrils at a branching point, but most often,
the fibrils were observed to split into two fibrils (b–d). In d, the branching
angle is close to 0 as also observed occasionally by TIRFM. Scale bar
represents 100 nm.Biophysical Journal 96(4) 1529–1536tered intensity increases abruptly and fluctuates as large
particles diffuse through the scattering volume. This occurs
after ~9 and 5 h for seed concentrations of 0.1 and
1 mg/mL, respectively. By visual inspection at the end of
the experiment, the glucagon samples formed transparent
gels with a few large millimeter-size white floccules
embedded in the gel. At the high seed concentration, more
and smaller floccules were seen. Even after several days,
no precipitation was visible in either cuvette.
DISCUSSION
Branching of glucagon ﬁbrils
Secondary nucleation designates any mechanism, in which
the instantaneous formation of new growth centers depend
on the fibril mass already formed. This can happen in several
a
c
b
d
FIGURE 5 Ab(1–40) and glucagon kinetics seeded with two different
seed concentrations and monitored by SALS at scattering angle q ¼
0.84 mm1 and by LALS at q ¼ 23 mm1. (a) SALS measurements on
Ab(1–40). The scattered intensity is plotted on separate axes with the
0.5 mg/mL data being plotted on the right-hand axis. The peptide solution
seeded with 0.5 mg/mL seeds has a linear increase in scattered intensity
for 12 h. At a seed concentration of 5 mg/mL, the linear phase lasts for 90
min, and after 8 h precipitation is observed. (b) LALS measurements on
Ab(1–40). The scattered intensity increases linearly, and an increase in
seed concentration increases the slope. The 5 mg/mL experiment was
stopped shortly after the kinetics had reached a plateau. (c) SALS measure-
ments on glucagon. The two reaction profiles are characterized by a long lag
phase: increasing the seed concentration 10-fold decreases the lag time from
~10 h to 5 h. (d) LALS measurements on glucagon. After a long lag phase,
the intensity increases irregularly as large particles diffuse through the scat-
tering volume.
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the purpose of this discussion, we classify secondary nucle-
ation into five different mechanisms according to the scheme
of Fig. 6 based on observations from the literature. First we
divide schemes into breaking and nonbreaking (Fig. 6). With
breaking, two new fibril ends are introduced. Smith et al.
(30) characterized the nanoscale properties of insulin fibrils
and found that a fibril 10 mm in length spontaneously breaks
on average every 47 min as a result of thermal fluctuations.
The nonbreaking mechanisms are further divided into two
classes: forking at the tip of the growing fibril and nucleus
formation on the fibril sides (lateral nucleation). Ruschak
and Miranker (11) concluded that the secondary process
involved in IAPP fibrillation could be surface-dependent
lateral nucleation. We divide lateral nucleation into cases
where the nucleus remains permanently attached to the
surface and cases where it can detach and diffuse into solu-
tion. Diffusible lateral nucleation has been observed in sickle
hemoglobin polymerization by Ferrone et al. (34). If the
nucleus instead remains attached to the surface, it either
forms a branch or continues to grow along the parent fibril,
which consequently thickens. Rogers et al. (31) propose
branching to be a mechanism involved in the formation of
insulin spherulites based on the constant density as function
of radius. Fibril thickening has been observed experimen-
tally (32,33). For example, in a time-lapse AFM study by
Jansen et al. (32), it was observed that the sides of early
insulin fibrils recruited oligomers through lateral interac-
tions, which led to thickening of the fibrils.
The most notable observation in the TIRFM study of
seeded solutions of glucagon is the fact that the fibrils not
only grow by linear elongation but also continuously create
new fibrils from the sides of existing fibrils. The newly
formed fibrils themselves can also form new fibrils by
branching, so we can classify the branching as isotomous,
meaning that all branches have equivalent properties. In
our opinion, the secondary nucleation mechanism most
consistent with the TIRFM observations is branching. Of
the mechanisms in Fig. 6, we readily exclude thickening
and forking. It is in principle possible that both breaking
and diffusible lateral nucleation could give rise to the
observed behavior, since the optical resolution of TIRFM
does not permit a detailed picture of a branch point.
However, the angular distribution (Fig. 3) shows that new
FIGURE 6 Classification of five secondary nucleation mechanisms.fibrils exclusively grow in the forward direction with
a preferred angle of 35–40. In the case of breaking, we
would expect the preferred angle to be centered around 0,
whereas the distribution would be isotropic if the nuclei
diffused away from the parent fibril before sticking to the
quartz again. We therefore classify the secondary nucleation
mechanism as branching. It is, in principle, possible to distin-
guish some of the secondary processes from each other by
a rigorous analysis of the kinetics’ dependence on monomer
concentration (2). However, glucagon fibrillation kinetics is
strongly affected by a concentration-dependent change in
fibril morphology, which makes such a kinetics analysis
impossible (14).
Using TEM, we were able to identify a number of cases
where a single fibril branched isotomously into two or several
fibrils (Fig. 4). Judging from the pictures, the fibrils do not
merely twine or untwine because the total number of filaments
that make up the fibrils appears larger after branching. The
fact that a single fibril was observed to branch into several
fibrils at a specific point makes it unlikely to be an artifact
from sample preparation (Fig. 4 a). In some cases, the fibril
split into two separate fibrils, which continued side by side
(Fig. 4 d). This could be an example of the events observed
occasionally by TIRFM, where newly formed fibrils grow
along the parent fibril for up to several micrometers.
We speculate that branches grow from defects created
during the growth process and therefore have a preferential
angle relative to the direction of growth. Defects might
form during growth by untwining of single protofilaments
from the main bundle, which then continues to grow. Later,
the dangling protofilament matures to a growing fibril. A
number of groups have reported fibrils splitting into protofi-
laments during growth without increasing the net number of
protofilaments (33,35–38). Most studies are static measure-
ments on fibrillated samples, but Goldsbury et al. (37)
described the same phenomenon using time-lapse AFM.
Their data show an example of a protofilament growing
out of a thicker fibril, which then continues growth in
a different direction (Fig. 3 b of Goldsbury et al. (37)). For
an untwining mechanism to support continuous branching
as shown in Fig. 2 b, the untwined protofilament must be re-
placed in the growing bundle, or the fibril would run out of
protofilaments to untwine. A similar mechanism should exist
to augment the dangling protofilament to a full-size fibril
capable of forming new branches itself.
Growth rates
Fibril lengths versus time were plotted in Fig. 3 b. Occasion-
ally fibrils temporarily stop growing. For example, after 5 h,
fibril 3 twice stops growing for ~50 min before resuming
growth. Although this could be caused by a local depletion
of monomers, the stop-and-run behavior could also result
from monomers being misaligned at the fibril end. If this is
the case, fibril growth would resume after the monomerBiophysical Journal 96(4) 1529–1536
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ated from the fibril end. We also note that of the six fibrils,
only two continue growth throughout the experiment (fibrils
2 and 4). The others stop growing after 3.7–9.7 h, although
fibrils in their vicinity keep growing. This could indicate
that the fibril ends of these fibrils have been permanently
terminated as a result of a misaligned monomer or perhaps
a morphology-dependent inhibition by a reversible glucagon
trimer as proposed in a previous study (14). The initial
growth rates were 40–140 nm/min, and after ~6 h, the growth
rates decreased to 20–40 nm/min. The decrease in growth
rates could indicate that fibril growth depletes monomers
locally, i.e., fibril growth is diffusion limited.
Ab(1–40) ﬁbril growth
Ab(1–40) fibril formation at physiological pH has been the
subject of many kinetic studies, but in terms of the lag phase
often with different conclusions. Some studies report
a pronounced lag phase of up to several days (18,22,39),
whereas others report no—or a very short—lag phase
(19,23–25). We note that lag phases are a rough measure
of the kinetics in spontaneous fibril growth and indicate
the time frame where only small amounts of fibrils and pre-
fibrillar aggregates are formed. Even small differences in
handling and solvent conditions can lead to very different
kinetics, and this may help explain the inconsistencies in
the lag times reported for Ab (40–42). The seeded reactions
used in this study circumvent these problems by bypassing
the primary formation of nuclei from monomers, which
can sometimes be difficult to reproduce in different experi-
mental settings, and focusing on the fastest part of the
kinetics: the fibril elongation. We note, however, that
although seeded reactions ensure lag phase reproducibility,
the elongation kinetics depends on the seed preparation
and is hence likely to vary from lab to lab.
Some of us previously performed real-time TIRFM exper-
iments on Ab(1–40) (18,21). The Ab(1–40) fibrils formed
radial star structures from clusters of seeds, but in contrast
to glucagon fibril growth, branching was never observed. It
has since been shown in a similar work by some of us that
the fibril assemblies are very sensitive to solvent conditions,
and we cannot rule out that under other conditions, Ab(1–40)
generates fibrils by a secondary nucleation mechanism (43).
The Ab(1–40) fibrils grew unidirectionally to a maximum
length of 15 mm, and after ~80 min monomers were depleted,
and fibril growth stopped. The fibril growth rate remained
constant at 300 nm/min. This fibril growth rate is signifi-
cantly higher compared to glucagon despite a lower molar
peptide concentration (50 mM and 72 mM, respectively).
Ab(1–40) fibril growth also exhibited stop-and-run behavior,
but the growth rates remained constant until monomers were
depleted. In the time-lapse AFM study by Goldsbury et al.
mentioned above (37), the growth rate of IAPP protofila-
ments on a mica surface was only ~1 nm/min, an effectBiophysical Journal 96(4) 1529–1536that may be caused by differences in the surface properties
of mica and quartz.
Theory of seeded ﬁbril growth
The observation in seeded TIRFM experiments that glucagon
fibrils support secondary nucleation, whereas Ab(1–40)
fibrils apparently do not, should result in fundamentally
different fibril mass growth for the two peptides. In the Sup-
porting Material, we derive the effect of changing seed
concentration on the initial part of the growth kinetics in
a very simple model of fibril growth with or without
secondary nucleation. We find that in the absence of
secondary nucleation, the increase in fibril mass will be linear
in time, with a slope proportional to the number of seed ends.
In the presence of secondary nucleation, the fibril mass
growth is exponential, and an increase in the seed concentra-
tion will give a shift on the time axis. These scenarios are
sketched in Fig. 7. It is seen that both the form of the seeded
fibrillation kinetics and the response to a change in seed
concentration are changed dramatically by the presence of
a secondary nucleation mechanism. We stress that the lag
phase in itself does not imply a secondary nucleation mecha-
nism as demonstrated by the work on microtubule polymeri-
zation by Flyvbjerg et al. (44). Only in the case of seeded
kinetics does the lag phase imply a secondary nucleation
mechanism. In all cases, the total fibril mass must at some
point converge toward a constant number, although this is
not taken into account in our simple model. At very high
seed concentrations, the lag phase will be bypassed altogether
even in presence of secondary nucleation (14).
Light-scattering data
We explored seeded fibrillation of Ab(1–40) and glucagon
by light scattering. Generally, the light-scattering signal
from a solution increases when the components aggregate
to form larger structures such as fibrils. The light scattered
FIGURE 7 Effect of changing the seed concentration on the initial part of
the fibrillation curve. (a) Seeding a kinetic process, in which secondary
nucleation is absent, affects the growth rate. Increasing the seed concentra-
tion increases the growth rate. (b) Seeding a kinetic process in which
secondary nucleation is present shortens the lag phase but does not affect
the growth rate.
Branching in Amyloid Fibril Growth 1535at small angles from a solution containing various fibrillar
species mainly comes from large structures, whereas smaller
species contribute relatively more at large angles. We use the
scattered intensity as a qualitative measure for the growth in
fibril mass, although it should be noted that the two are not
directly proportional. For example, fibrils bundling together
forming large structures can give rise to an increase in the
scattered intensity, in particular at small angles, without an
increase in fibril mass.
The light-scattering data in Fig. 5 show good agreement
with the simple theory. The fibrillation of Ab(1–40) starts
immediately at the beginning of the experiment and proceeds
approximately linearly (Fig. 5, a and b). As expected from
the model without secondary nucleation, the slope is higher
at 5 mg/mL seed concentration than at 0.5 mg/mL seed
concentration. At 5 mg/mL seed concentration, the fibrilla-
tion process stops after ~1 h, in good agreement with the
~80 min of growth observed by TIRFM (18). For glucagon,
the picture is quite different (Fig. 5, c and d): at both seed
concentrations, several hours of lag phase without detectable
growth of fibrils or prefibrillar species is followed by an
abrupt increase in fibril mass. The lag time is shorter in the
experiment with 1 mg/mL than with 0.1 mg/mL seeds in
agreement with the predictions of the model, which includes
secondary nucleation.
The simple model predicts that in the absence of
a secondary nucleation mechanism, the slope of the mass
growth curve should increase 10-fold when 10 times more
seeds are added. We do not obtain quantitative agreement
between the growth rates of the scattered intensity and this
prediction. This could be because the light-scattering signal
is not strictly proportional to the total mass as well as because
of inaccuracies in the model’s simplified picture of fibrilla-
tion. However, we find it significant that the predicted differ-
ence in seeded fibril growth with and without secondary
nucleation clearly stands out in our data and agrees with
the observations from TIRFM.
The SALS signal in the glucagon experiment with 1mg/mL
seed is already quite large at t¼ 0. The initial SALS signal in
the experiment with 0.1 mg/mL seeds is one order of magni-
tude lower, indicating that the signal at t¼ 0 is caused by scat-
tering from the seeds. The LALS signal from the glucagon
samples show large fluctuations at both seed concentrations.
This shows that the number of scatterers in the 2$103 mm3
detection volume fluctuates strongly because of the low total
number density. The signals from the Ab(1–40) samples fluc-
tuate significantly less, which shows a higher number density
of scatterers. We conclude that our procedure for making
fibril seeds generates fewer and larger seeds for glucagon
than for Ab(1–40).
CONCLUSION
Our TIRFM movies of seeded glucagon fibril formation
very clearly show repeated branching. The presence andimportance of branching in bulk volume are supported by
light-scattering experiments inwhichweobserve the signature
expected from a simple theory of fibril growthwith branching:
a sigmoid growth curve, with the lag phase decreased by
increase of seed concentration. For Ab(1–40), for which no
branchingwas observed byTIRFM, a quite different signature
is observed in the light scattering experiments.
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